Capricor Therapeutics stock rises on Piper Sandler upgrade

Capricor Therapeutics (CAPR) shares rose 20% after-hours on positive Hope-3 extension data showing slower upper-limb deterioration in patients treated with Deramiocel. The FDA is reviewing the data for a Nov. 22 decision. CAPR closed at $8.57, down 2% for the day and 14% for the month. Analysts and retail traders anticipate potential upside ahead of the FDA decision.

Capricor Therapeutics (CAPR) shares rose after presenting data on deramiocel, its experimental Duchenne muscular dystrophy treatment, at the World Muscle Society Congress. The data showed longer-term effects of the therapy, prompting investor interest. According to the company, this could be a significant development for its pipeline. Investors reacted positively to the news, driving up the stock price in late trading Tuesday.

Capricor Therapeutics (CAPR) shares dropped 8% on Friday as investors await the FDA's decision on its drug Deramiocel. The FDA's target action date is Saturday. The company plans to submit an amendment with additional data. Activist shareholder Kaos Capital is pushing for a board shakeup and cost-cutting measures. CAPR stock is down 78% year-to-date.

Capricor Therapeutics (CAPR) stock surged 9.2% pre-market to $9.14 after B.Riley upgraded it to Buy with a $21 price target, up from $5. The firm cited the potential of deramiocel, an investigational cell therapy for Duchenne muscular dystrophy, ahead of a key FDA decision in November 2026. B.Riley's reversal follows upgrades from other analysts, with Cantor Fitzgerald, Piper Sandler, and Oppenheimer also bullish on the stock. The rally occurred despite a broader market decline, highlighting the

B. Riley upgraded Capricor Therapeutics (CAPR) to Buy from Neutral, raising its price target to $21 from $5. The analyst anticipates potential re-rating before the FDA decision on November 22, with data possibly released at the World Muscle Society conference on October 3. B. Riley sees 50% upside in a positive scenario and expects shares to hold near current levels in a negative scenario.

Capricor Therapeutics (CAPR) stock surged 144% in a month due to positive phase III data for its cell therapy deramiocel, renewed FDA engagement, and a refined regulatory pathway. The FDA accepted additional data and extended the PDUFA date to November 22, 2026, focusing on upper-limb function. Investors are optimistic despite regulatory risks, with the upcoming FDA decision being a major catalyst.